Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital Partners in a deal potentially worth up to $96 million.

The majority of Berkshire Hathaway (BRK.B) (BRK.A) investors' money is in equities, and that preference won't change, Warren Buffett said in his annual shareholders' letter on Saturday.